| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
109,470,000 |
| Market
Cap: |
49.48(M) |
| Last
Volume: |
627,989 |
Avg
Vol: |
622,932 |
| 52
Week Range: |
$0.3065 - $0.9871 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
| |
NASDAQ BIOTECHNOLOGY |
|
NASDAQ COMPOSITE |
| |
NASDAQ NNM COMPOSITE |
|
Rankings:
|
|
| Insider 3 Months : 5.8 |
| Insider 6 Months : 5.8 |
| Insider 3/6 Months : 11.9 |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Vaxart is a clinical-stage biotechnology company primarily focused on the development of oral recombinant vaccines based on its Vector-Adjuvant-Antigen Standardized Technology proprietary oral vaccine platform. Co.'s oral vaccines are designed to generate immune responses that protect against a range of infectious diseases and may be useful for the treatment of chronic viral infections and cancer. Co.'s investigational vaccines are administered using a room temperature-stable tablet, rather than by injection. In addition, Co. is in early development of its first therapeutic vaccine targeting cervical cancer and dysplasia caused by human papillomavirus.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
100,000 |
100,000 |
100,000 |
120,000 |
| Total Buy Value |
$49,000 |
$49,000 |
$49,000 |
$62,578 |
| Total People Bought |
1 |
1 |
1 |
2 |
| Total Buy Transactions |
1 |
1 |
1 |
2 |
| Total Shares Sold |
0 |
0 |
0 |
0 |
| Total Sell Value |
$0 |
$0 |
$0 |
$0 |
| Total People Sold |
0 |
0 |
0 |
0 |
| Total Sell Transactions |
0 |
0 |
0 |
0 |
| End Date |
2025-03-30 |
2024-12-27 |
2024-06-28 |
2023-06-29 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Finney Michael J. |
Director |
• • – |
2025-06-13 |
4 |
A |
$0.00 |
$0 |
D/D |
16,000 |
702,840 |
|
- |
|
| Finney Kevin |
Director |
• • – |
2025-06-13 |
4 |
A |
$0.00 |
$0 |
D/D |
6,103 |
38,103 |
|
- |
|
| Watson W. Mark |
Director |
• • – |
2025-06-13 |
4 |
A |
$0.00 |
$0 |
D/D |
16,000 |
94,125 |
|
- |
|
| Wheadon David E. |
Director |
• • – |
2025-06-13 |
4 |
A |
$0.00 |
$0 |
D/D |
16,000 |
46,750 |
|
- |
|
| Heron Elaine J |
Director |
• • – |
2025-06-13 |
4 |
A |
$0.00 |
$0 |
D/D |
16,000 |
56,566 |
|
- |
|
| Grasman Jeroen Nicolaas |
Chief Financial Officer |
• • – |
2025-05-19 |
4 |
A |
$0.00 |
$0 |
D/D |
350,000 |
350,000 |
|
- |
|
| Lo Steven |
President, Chief Exec Officer |
• • – |
2025-05-19 |
4 |
B |
$0.49 |
$49,000 |
I/I |
100,000 |
100,000 |
2.66 |
-1% |
|
| Cummings James F. |
Chief Medical Officer |
• • – |
2025-03-28 |
4 |
D |
$0.42 |
$1,387 |
D/D |
(3,292) |
745,757 |
|
- |
|
| Tucker Sean |
SVP, Chief Scientific Officer |
• • – |
2025-03-28 |
4 |
D |
$0.42 |
$1,648 |
D/D |
(3,913) |
740,490 |
|
- |
|
| Lo Steven |
President, Chief Exec Officer |
• • – |
2025-03-18 |
4 |
D |
$0.57 |
$12,751 |
D/D |
(22,362) |
227,638 |
|
- |
|
| Cummings James F. |
Chief Medical Officer |
• • – |
2025-03-18 |
4 |
D |
$0.57 |
$3,861 |
D/D |
(6,772) |
343,049 |
|
- |
|
| Lee Phillip E |
Chief Financial Officer |
• • – |
2025-03-18 |
4 |
D |
$0.57 |
$4,590 |
D/D |
(8,050) |
225,619 |
|
- |
|
| Berg Edward B |
SVP, General Counsel |
• • – |
2025-03-18 |
4 |
D |
$0.57 |
$4,590 |
D/D |
(8,050) |
288,123 |
|
- |
|
| Tucker Sean |
SVP, Chief Scientific Officer |
• • – |
2025-03-18 |
4 |
D |
$0.57 |
$4,590 |
D/D |
(8,050) |
338,403 |
|
- |
|
| Cummings James F. |
Chief Medical Officer |
• • – |
2025-02-02 |
4 |
D |
$0.68 |
$5,414 |
D/D |
(7,964) |
318,837 |
|
- |
|
| Tucker Sean |
SVP, Chief Scientific Officer |
• • – |
2025-02-02 |
4 |
D |
$0.68 |
$6,283 |
D/D |
(9,242) |
346,453 |
|
- |
|
| Berg Edward B |
SVP, General Counsel |
• • – |
2025-02-02 |
4 |
D |
$0.68 |
$6,283 |
D/D |
(9,242) |
261,464 |
|
- |
|
| Finney Kevin |
Director |
• • – |
2025-01-28 |
4 |
A |
$0.00 |
$0 |
D/D |
32,000 |
32,000 |
|
- |
|
| Lee Phillip E |
Chief Financial Officer |
• • – |
2024-12-15 |
4 |
D |
$0.59 |
$3,630 |
D/D |
(6,132) |
233,669 |
|
- |
|
| Watson W. Mark |
Director |
• • – |
2024-06-18 |
4 |
B |
$0.68 |
$13,578 |
D/D |
20,000 |
78,125 |
2.39 |
22% |
|
| Lee Phillip E |
Chief Financial Officer |
• • – |
2024-06-12 |
4 |
D |
$0.76 |
$1,525 |
D/D |
(2,007) |
239,801 |
|
- |
|
| Watson W. Mark |
Director |
• • – |
2024-06-11 |
4 |
A |
$0.00 |
$0 |
D/D |
16,000 |
58,125 |
|
- |
|
| Wheadon David E. |
Director |
• • – |
2024-06-11 |
4 |
A |
$0.00 |
$0 |
D/D |
16,000 |
30,750 |
|
- |
|
| Finney Michael J. |
Director |
• • – |
2024-06-11 |
4 |
A |
$0.00 |
$0 |
D/D |
16,000 |
686,840 |
|
- |
|
| Yedid Robert A. |
Director |
• • – |
2024-06-11 |
4 |
A |
$0.00 |
$0 |
D/D |
16,000 |
34,490 |
|
- |
|
200 Records found
|
|
Page 1 of 8 |
|
|
0.04 (8.59%) 
